| CAS NO: | 853220-52-7 |
| 包装 | 价格(元) |
| 10mM (in 1mL DMSO) | 电议 |
| 10mg | 电议 |
| 50mg | 电议 |
| 200mg | 电议 |
| Cas No. | 853220-52-7 |
| 别名 | WNTAGONIST1(CID11210285盐酸盐),BML-284 |
| 化学名 | (Z)-1-(benzo[d][1,3]dioxol-5-yl)-N-(2-imino-6-(3-methoxyphenyl)-2,3-dihydropyrimidin-4(1H)-ylidene)methanamine hydrochloride |
| Canonical SMILES | COC1=CC=CC(C(NC2=N)=C/C(N2)=N/CC3=CC4=C(OCO4)C=C3)=C1.Cl |
| 分子式 | C19H19ClN4O3 |
| 分子量 | 386.83 |
| 溶解度 | ≥ 38.7mg/mL in DMSO |
| 储存条件 | Store at -20℃ |
| General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while. |
| Shipping Condition | Evaluation sample solution : ship with blue ice All other available size: ship with RT , or blue ice upon request |
| 产品描述 | Wnt agonist 1 is a small-molecule agonist of Wnt signaling pathway [1]. The Wnt signaling pathway is an important signal transduction pathway that involved in a variety of physiological and pathological processes by regulating genes involved in cellular adhesion, proliferation, and differentiation [1]. Wnt agonist 1 is a cell-permeable Wnt signaling pathway agonist. Wnt agonist 1 induced b-catenin- and TCF-dependent transcriptional activity in a dose-dependent way with EC50 of 0.7 μM. In Xenopus embryos, treatment with Wnt agonist 1 (10 μM) from developmental stage 10.5 to stage 40 resulted in substantial head defects, such as diminished heads and complete loss of eyes, and reduced eyes and heads. This phenotype is similar to that which results from Wnt over-expression in head specification during early embryonic development. Reference: |
m.cnreagent.com